4.Recent Progress on Pharmaceutical Properties of Extracellular Vesicles from Mesenchymal Stem Cells--Review.
Yu-Shuang LIU ; Yuan SUN ; Zi-Kuan GUO
Journal of Experimental Hematology 2023;31(4):1247-1251
Mesenchymal stem cells (MSCs) have been officially approved in many countries to treat graft-versus-host disease, autoimmune disorders and those associated with tissue regeneration after hematopoietic stem cell transplantation. Studies in recent years have confirmed that MSC acts mainly through paracrine mechanism, in which extracellular vesicles secreted by MSC (MSC-EV) play a central role. MSC-EV has overwhelming advantages over MSC itself in the setting of adverse effects in clinical application, indicating that MSC-EV might take the place of its parent cells to be a potentially therapeutic tool for "cell-free therapy". The pharmaceutical properties of MSC-EV largely depend upon the practical and optimal techniques including large-scale expansion of MSC, the modification of MSC based on the indications and the in vivo dynamic features of MSC-EV, and the methods for preparing and harvesting large amounts of MSC-EV. The recent progresses on the issues above will be briefly reviewed.
Humans
;
Extracellular Vesicles
;
Hematopoietic Stem Cell Transplantation/adverse effects*
;
Mesenchymal Stem Cell Transplantation/methods*
;
Mesenchymal Stem Cells
;
Pharmaceutical Preparations
5.Efficacy and safety of tandem autologous stem cell transplantation in multiple myeloma: a retrospective single-center analysis.
Shunquan WU ; Zongjian QIU ; Ting LIN ; Zhijuan ZHU ; Xiaofan LI ; Xianling CHEN ; Ping CHEN ; Yiting WANG ; Rong ZHAN ; Nainong LI
Chinese Medical Journal 2023;136(15):1873-1875
10.Novel strategy and latest research progress on treatment of acute graft versus host disease.
Bo TANG ; Heng ZHU ; Fan ZHOU ; Yi ZHANG
Journal of Experimental Hematology 2014;22(2):543-548
Acute graft-versus-host disease (aGVHD) is the major complication associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) and the major cause of morbidity and mortality following allo-HSCT. Diagnosis of aGVHD is typically based on clinical symptoms and confirmed by biopsy. Once aGVHD has occurrence, the steroids should be the first choice of treatment. However, if the treatment with steroids failed, the prognosis would be poor. In recent years, the novel strategies for the treatment of aGVHD have been developed. In this article, the clinical features, pathogenesis and novel strategies, including mAb treatment, physical and cell therapies are briefly summarized.
Acute Disease
;
Graft vs Host Disease
;
therapy
;
Hematopoietic Stem Cell Transplantation
;
adverse effects
;
Humans
;
Transplantation, Homologous
;
adverse effects
Result Analysis
Print
Save
E-mail